Tag Archives: advaxis

July, 2018

13 July
FDA Lifts Clinical Hold on Advaxis’ Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug (IND) application for its Phase 1/2 study of axalimogene filolisbac (AXAL) …
Share

25 January
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated study evaluating the Company’s proprietary Lm-based antigen delivery product, axalimogene filolisbac (ADXS11-001), in combination with chemoradiation as a treatment for high-risk, locally advanced anal cancer were …
Share

7 March
FDA Accepts Advaxis’ IND for Amgen-Partnered Personalized Cancer Immunotherapy

PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has indicated the Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in …
Share

27 February
Advaxis Licenses Antigen Delivery Technology to Sellas for Development of Targeted Cancer Immunotherapy

PRINCETON, N.J., and HAMILTON, Bermuda, Feb. 27, 2017 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on developing cancer immunotherapies, today announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm-based antigen delivery …
Share

2 August
Amgen and Advaxis Enter Cancer Immunotherapies Collaboration

THOUSAND OAKS, Calif. and PRINCETON, N.J., Aug. 2, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient’s immune system to respond against the unique …
Share

21 July
Advaxis’ AXAL Receives Fast Track Designation from the FDA for Treatment of Cervical Cancer

PRINCETON, N.J., July 21, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead immunotherapy candidate, axalimogene filolisbac (AXAL), as a Fast Track product for adjuvant therapy for high-risk locally …
Share

16 December
FDA Lifts IND Clinical Hold for Three of Advaxis’ Product Candidates

PRINCETON, N.J., Dec. 16, 2015 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac …
Share

11 February
Advaxis and Incyte Strike Cancer Immunotherapy Deal

Advaxis, Inc. has signed a deal with Incyte Corporation to evaluate the combination of the companies’ investigational cancer immunotherapies. The companies announced that they have entered into a clinical trial collaboration agreement to study the combination of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s oral indoleamine 2,3-dioxygenase 1 (IDO1) …
Share